• KOLs
  • Deep Vein
  • Enrico Bernardi
Enrico Bernardi

Enrico Bernardi

Dept Of Emergency Medicine, Ulss 2 Marca Trevigiana – Ospedale Di Treviso, Treviso, Italy

Direct Impact

Concepts for which Enrico Bernardi has direct influence:

deep vein
extended ultrasonography
lower extremities
venous thrombosis
clinically symptomatic
normal abnormal

External impact

Concepts related to the work of other authors for which Enrico Bernardi has influence:

predictive role
acute normotensive pulmonary embolism
modified bova
european union-28
covid-19 outbreak
indirect costs
hot-pe trial

Prominent publications by Enrico Bernardi

KOL-Index: 79 BACKGROUND: The Bova score has shown usefulness in the identification of intermediate-high risk patients with acute pulmonary embolism (PE), but lacks prospective validation. The aim of this study was to prospectively validate the Bova score in different settings from the original derivation cohort. METHODS: Consecutive, normotensive patients with acute PE recruited at 13 academic or general ...
Known for
13 Academic Hospitals | 30-Day Composite | Pe-Related Complication Rate | Normotensive Acute
KOL-Index: 32 INTRODUCTION: Early discharge of patients with acute low-risk pulmonary embolism requires validation by prospective trials with clinical and quality-of-life outcomes. METHODS: The multinational Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE) single-arm management trial investigated early discharge followed by ambulatory ...
Known for
Improved Months | Generic Acts | Discharge Ambulatory | Improvement Pemb
KOL-Index: 24 BACKGROUND: The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients. ...
Known for
Inhibitors Lower | Statistical Aceis | Rate Admission
KOL-Index: 13 AIMS: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. METHODS AND RESULTS: We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility ...
Known for
Low-Risk Acute | Symptomatic Non-Fatal Vte Recurrence | International Multicentre Single-Arm Trial | Oral Factor Inhibitor Rivaroxaban
KOL-Index: 8 Spatial variability represents a challenge for viticulture. Variable-rate fertilization is a promising technology to manage different vigor and yield zones within the. In this study, on-the-go variable rate fertilization system was implemented and tested, based on commercial spectral sensors. GreenSeeker Normalized Difference Vegetation Index (NDVI) sensor was mounted in front of a tractor ...
Known for
Rate Spreader | Viticulture | Sample Points | Agronomist Expertise
KOL-Index: 5 BACKGROUND: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. METHODS: A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected ...
Known for
Conclusions | Priori Expected Rates | Primary Intention-To-Treat Phase | 2
KOL-Index: 4
Known for
Dimensional Problems | Clusterized Copula

Dept of Emergency Medicine, ULSS 2 Marca Trevigiana – Ospedale di Treviso, Treviso, Italy

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172